Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00045318 · ClinicalTrials.gov registry record · Phase 1

Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction

A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.

Completed
Registry status
Phase 1
Development phase

NCT00045318: Completed Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.

NCT00045318 is a Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00045318, a Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of exatecan mesylate in treating patients who have advanced solid tumors and kidney dysfunction.

Interventions

  • DRUG exatecan mesylate

Trial Details

FieldValue
Start Date 2002-05
Est. Completion 2007-10
Phase Phase 1
Jonsson Comprehensive Cancer Center

321 total trials

What the finished NCT00045318 record still lists

NCT00045318 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which exatecan mesylate is the first listed.

NCT00045318 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00045318 about?

NCT00045318 is a clinical study titled "Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of exatecan mesylate in treating patients who have advanced solid tumors and kidney dysfunction.

What is the current status of trial NCT00045318?

This trial is currently completed. It is a Phase 1 study. The study started on 2002-05. Estimated completion is 2007-10.

What interventions are being tested in trial NCT00045318?

The interventions under investigation include: exatecan mesylate (DRUG).

Who is sponsoring clinical trial NCT00045318?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00045318, the US trial registry maintained by the National Library of Medicine. NCT00045318 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.